Drug intelligence / Profile preview

QR-334

Development stage: Preclinical
Lead developer: Quigley Pharma
Modality: Small Molecules

Overview

QR-334 is a pharmaceutical compound that was under investigation for the treatment of sialorrhea, which is characterized by excessive secretion of saliva from the salivary glands. The drug was being developed by Quigley Pharma, a subsidiary of Quigley Corporation. Its precise mechanism of action has not been publicly disclosed, and there are no reports indicating approval or late-stage clinical development. The available information suggests it was in early-stage research as a potential therapy for sialorrhea[1][2][3][4].

Other names: qr-334qr334qr 334

Beyond the preview

Go deeper on QR-334.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR-334.

Explore the full profile